TAE Life Sciences

TAE Technologies has developed a high-intensity beam system that shoots energetic particles at clouds of plasma to boost stability and performance. TAE Life Sciences aims to use similar beams for an application known as boron neutron capture therapy, or BNCT. The technique involves injecting a drug containing non-radioactive boron into a cancer patient’s tumor, and then shooting a neutron beam at the tumor. The boron atoms absorb the neutrons, resulting in a localized radiation effect that kills the tumor cells while preserving non-cancerous tissue. BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy.




Robert Hill, CEO

Kendall Morrison, Ph.D., Chief Science Officer